Adaptin Bio (APTN) Operating Expenses (2023 - 2026)

Adaptin Bio (APTN) has 4 years of Operating Expenses data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 34.53% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $5.7 million (up 82.93% YoY), and the FY2025 full-year result was $5.4 million, up 110.71% from the prior year.
• Operating Expenses fell to $1.1 million in Q1 2026, from $1.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $1.7 million in Q3 2025 to a low of $34155.0 in Q4 2023.
• A 4-year average of $836915.8 and a median of $850458.0 in 2025 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 2216.71% in 2024 and soared 34.53% in 2026, its largest moves.
• Tracing APTN's Operating Expenses over 4 years: stood at $34155.0 in 2023, then surged by 1387.57% to $508080.0 in 2024, then soared by 169.25% to $1.4 million in 2025, then retreated by 16.36% to $1.1 million in 2026.
• Business Quant data shows APTN's Operating Expenses at $1.1 million in Q1 2026, $1.4 million in Q4 2025, and $1.7 million in Q3 2025.